TIMI研究组:JACC焦点研讨会2/8
本文回顾了TIMI(心肌梗死溶栓)研究组自1984年由NHLBI成立以来的发展历程,从早期急性心肌梗死溶栓治疗试验扩展至稳定冠心病、脑血管病、外周动脉疾病、血脂异常、心力衰竭、房颤、糖尿病和肥胖等广泛领域,已完成超过70项试验。文章总结了部分已完成试验及其主要经验教训,并讨论了进行中的试验和未来方向。
要点
- TIMI研究组成立于1984年,最初研究急性心肌梗死溶栓治疗的有效性与安全性。
- 研究范围已扩展至多种心血管疾病及代谢性疾病,涉及溶栓、抗栓、调脂、抗炎、心衰、降糖和减重等多种干预。
- TIMI现已完成超过70项试验,本文综述其起源、主要经验教训及未来方向。
核心结论
- TIMI研究组从急性心肌梗死溶栓研究起步,已发展为覆盖多疾病领域的大型学术研究组织,完成超过70项试验。
研究设计与样本
- 本文为综述,描述TIMI研究组的起源、已完成的试验及主要经验教训,并讨论进行中的试验和未来方向。
主要发现
- TIMI研究组最初由NHLBI支持完成3项溶栓治疗临床试验,后成为以布莱根妇女医院为总部的学术研究组织。
- TIMI研究组已研究包括稳定冠心病、脑血管病、外周动脉疾病、血脂异常、心力衰竭、心房颤动、糖尿病和肥胖在内的广泛患者人群。
- TIMI研究组已研究溶栓、抗血栓、调脂、抗炎、心力衰竭、降糖和减重等多种干预措施。
- TIMI研究组现已进入第37年,完成超过70项试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In 1984, the National Heart, Lung, and Blood Institute (NHLBI) decided to study the efficacy and safety of the treatment of acute myocardial infarction with an emerging therapy, coronary thrombolysis, and thus the TIMI (Thrombolysis In Myocardial Infarction) Study Group was born. Following completion of 3 clinical trials of thrombolytic therapy supported by the NHLBI, TIMI became an academic research organization headquartered at Brigham and Women's Hospital and subsequently branched out to study a wide range of patients, including those with stable coronary, cerebrovascular, and peripheral arterial disease; dyslipidemia; heart failure; atrial fibrillation; diabetes; and obesity. TIMI also began to study a wide range of interventions including thrombolytic, antithrombotic, lipid-modifying, anti-inflammatory, heart failure, glucose-lowering, and weight loss agents. TIMI, now in its 37th year, has completed >70 trials. This review describes the origins of the TIMI Study Group, summarizes several of its completed trials and the major lessons learned from them, and discusses ongoing trials and future directions.
引用
- Sabatine MS, Braunwald E. Thrombolysis In Myocardial Infarction (TIMI) Study Group: JACC Focus Seminar 2/8. J Am Coll Cardiol. 2021. PMID: 34082913. doi:10.1016/j.jacc.2021.01.060
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。